HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target

Benzinga · 10/15 09:57
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $60 price target.